Announcement under Regulation 30 (LODR)-Press Release / Media Release
Filed with BSE · ISIN INE194R01017 · · 4 pages · English
Summary by 6ix AI
Fredun Pharmaceuticals Ltd. has issued a press release detailing its strategic transformation into a brand-led healthcare platform, focusing on pet care and wellness products. The company is expanding its operations through significant investments in pet healthcare, including acquisitions and the launch of new products. Fredun aims to transition to a fully branded portfolio by a specified future date, targeting substantial growth in revenue and profitability. The filing also highlights the company's capacity expansion plans and its commitment to enhancing shareholder value through bonus share allotments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Fredun Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Fredun Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Allotment
- Revised Outcome Of Board Meeting Dated 03Rd October, 2026.
- Board Meeting Outcome for Allotment Of 1,82,400 Equity Shares To Non-Promoter Allottees Pursuant To Conversion Of 60,800 Warrants Into Equity Shares, Consequent To The 1: 2 Bonus Issue.
- Fredun Pharmaceuticals Ltd. Press Release Sep 22 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 15 2026
Later from Fredun Pharmaceuticals
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Board Meeting Outcome for Outcome Of The Board Meeting
- Financial Results For The Quarter Ended 30Th September, 2026.
- Approved The Proposal For Making An Application To National Stock Exchange Of India Limited (NSE) For Listing And Trading Of The Equity Shares Of The Company On NSE.
Follow Fredun Pharmaceuticals into a list and get an email when it puts out news.
Follow Fredun Pharmaceuticals